Category Archives: Integrative Medicine

LOS ANGELES GTs Synergythe beloved and world-renowned Kombucha brand, today announced a partnership withChopra Global, a leading whole health platform founded by Dr. Deepak Chopra. GTs Synergy is the first-ever branded content partner of Chopra Global; the two brands are joining forces in support of GTs recently launched Rooted In Nature campaign to reinforce the message thatholistic health for mind, body, and soul are all rooted in the natural world.

GTs Synergy and Chopra Global aim to provide the world with tools and resources for mental health and wellness maintenance. Starting today, new GTs email subscribers can receive free GTs Synergy Kombucha and a complimentary 1-year membership to Chopra Globals new Meditation and Well-Being App, while supplies last. The Chopra App features a comprehensive library of simple self-care guidance and meditations for mind, body and spirit to help create and sustain a healthier life. Chopra Global launched its app offering in September and is currently available on iOS.

At GTs, everything we do is rooted in our mission to be a guide and helping hand for peoples health & wellness journeys. With Chopra Global by our side as part of our Rooted In Nature campaign, together we can reach even more people to share a message that a healthy mind is just as important as a healthy body, says GT Dave, Founder and CEO of GTs Living Foods. For 25 years, Chopra Global and GTs alike have pioneered our respective industries with approaches inspired by Eastern philosophies and the natural world. Now more than ever, in our increasingly modern lives, so many people are losing that connection to nature and self-care. We are honored and grateful to partner with Chopra Global to emphasize the importance of Mother Nature and meditation as part of a healthier, more holistic way of living.

Many brands market their commitment to the consumers well-being, yet few actually invest in that mission, says Tonia OConnor, CEO of Chopra Global. GTs, like Chopra Global, was founded on the platform of advancing well-being and promoting healthy lifestyles. Offering their subscribers free access to our new well-being and meditation subscription app further demonstrates GTs dedication to serving its customers. We are thrilled to partner with a company that values Chopra Globals self-care guidance and the opportunity to share a co-produced content series with new audiences in different formats.

For more than two decades, Chopra Global has been at the forefront of health and wellness, empowering personal transformation for millions of people worldwide to expand our collective well-being. Anchored by the lifes practice and research of Dr.Deepak Chopra, a pioneer in the fields of integrative medicine, consciousness, and meditation, Chopra Globals signature programs have been proven to improve overall well-being through a focus on physical, mental, and spiritual health.

Additionally, GTs will present a special Chopra Globalco-produced digital meditation series in November that will offer bite-sized guided meditations focused on gratitude and the importance of being in nature. The series will feature Chopra Globals trained and certified instructors along with special appearances fromChopra Global CEO Tonia OConnor, and the health and wellness pioneer himself,GT Dave.

GTs Meditation Series will be completely free and available via GTs and Chopra Globals social channels.

For more information on GTs Living Foods and the Chopra Global partnership, please visit:GTsLivingFoods.com/rootedand follow along on social media: @GTsKombucha.

About GTs Living Foods:

We believe that Mother Nature is the Worlds greatest healer. Since 1995, GTs Living Foods has revolutionized how people think and feel about Kombucha and fermented foods in the Western World. From the womb, founder GT Dave was raised vegetarian and taught that food can be medicine. He continues to uphold that philosophy with always pure, potent, and plant-derived fermented offerings produced in their most authentic form, never compromised. The fiercely independent, family-owned, and operated company is available in over 55,000 retailers across North America and Europe. Today and beyond, GTs Living Foods driving purpose is to spread a global message that food can be medicine and through proper nutrition, one can heal thyself. For more information, please visitgtslivingfoods.com.For more information, interact with the team onFacebook,TwitterandInstagram.

About Chopra Global:

Chopra Global is a leading whole health company that is empowering personal transformation for millions of people globally to expand our collective well-being. Anchored by the lifes practice and research of Dr.Deepak Chopra, a pioneer in integrative medicine, Chopra Globals signature programs have been proven to improve overall well-being through a focus on physical, mental and spiritual health. Chopra Global has been at the forefront of health and wellness for more than two decades with a portfolio that includes an editorial archive of more than 2000 health articles, expansive self-care practices and meditations, a comprehensive mobile app, masterclasses, teacher certifications, immersive live events and personalized retreats. By providing tools, guidance and community, Chopra aims to advance a culture of well-being and make a healthy, peaceful and joyful life accessible to all. For more information, interact with the team onFacebook,TwitterandInstagram.

About Deepak Chopra:

Dr.Deepak Chopraisa world-renowned pioneer in integrative medicine and personal transformation. He isthe founder ofChopra GlobalandThe Chopra Foundation, a non-profit entity for research on well-being and humanitarianism.Chopra is a Clinical Professor of Family Medicine and Public Health at theUniversity of California, San Diegoand serves as a senior scientist with Gallup Organization.For the last thirty years, Chopra has been at the forefront of the meditation revolutionand has authored over 90 books translated into over forty-three languages, including numerousNew York Timesbestsellers.His newest book,Total Meditation(Harmony Book,September 2020) helps to achieve new dimensions of stress-free and joyful living.TIME magazine has described Dr. Chopra as one of the top 100 heroes and icons of the century.

For More Information:https://www.gtslivingfoods.com

Go here to read the rest:
GT's Synergy Teams Up With Chopra Global For First-Ever National Partnership - BevNET.com

PARIS, Oct. 28, 2020 /PRNewswire/ -- Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce thatNational Institute of Integrative Medicine's (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA)positive Circulating Tumor Cells (CTC).

The peer-reviewed article published in the journalFrontiers in Oncology (article), shows that the prostate cancer test based on CTC harvested with the ISET technology and identified by the Immuno-Cytochemistry (ICC) PSA marker has an estimated positive-predictive-value (PPV) of 99% and negative-predictive-value (NPV) of 97%, providing a more reliable screening test for prostate cancer than the standard PSA blood test (PPV = 25%; NPV = 15.5%).

Prostate cancer is the second most common cancer and the fifth leading cause of cancer deaths in men worldwide. Due to the limited sensitivity and specificity of the standard PSA test, a relevant proportion, close to 75%, of unnecessary prostate biopsies are performed every year, generating avoidable costs and suffering.

"This new non-invasive test based on ISET technology allows for early detection of prostate cancer more accurately than the standard PSA test. Improving the accuracy of tests for early cancer detection may reduce the burden of unnecessary biopsies," said NIIM Director of Research, and Chief Investigator Associate Professor Karin Ried.

Davide Brechot, Deputy Director and CTO at Rarecells commented: "NIIM's preliminary data obtained with the ISET technology opens the way to a more reliable prostate cancer screening test driving earlier curative interventions while reducing unnecessary, painful and costly prostate biopsies.They add to the body of published evidence of ISET technology's excellence in cancer diagnostics and management"

ISET has been validated by more than 85 independent scientific publications on 3,400 cancer patients and more than 1,200 cancer-free individuals (see http://www.rarecells.com). It demonstrates unparalleled performance for the isolation and characterization of individual CTC and CTC clusters.

About RARECELLS (www.rarecells.com)

Rarecells develops high value, innovative diagnostic tests in the fields of liquid biopsy and early cancer diagnostics. The company is the exclusive licensee of the ISET patent portfolios owned by University of Paris, INSERM and Assistance Publique-Hpitaux de Paris (AP-HP).

Logo - https://mma.prnewswire.com/media/1280816/Rarecells_Diagnostics_Logo.jpg

[emailprotected]

SOURCE Rarecells, Inc.

Home

The rest is here:
ISET test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells - PRNewswire

TORONTO, Oct. 28, 2020 (GLOBE NEWSWIRE) -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (CB2 or the Company), one of the largest multi-specialty healthcare systems in the United States, is pleased to announce that it has completed the asset acquisition of Tacoma-based medical clinic owned by Dr. Jackson (JMC) in University Place, Washington. The acquisition of JMC expands the Companys bricks and mortar and telemedicine services to 15 States.

JMC has been operating in Washington for over 20 years and has a growing patient base of over 10,000 from its operations. Services to patients include primary care and urgent care. Services provided by JMC are primarily reimbursed through insurance carriers including Medicare, Medicaid and other commercial payors. The Company can expect to leverage the expertise of management and operations across its network of existing clinics to further optimize organic growth activities.

The Company anticipates continued growth in patient registrations and visits as JMC continues to thrive among the challenges most clinics have faced due to the recent COVID-19 pandemic. Further, the Company will work quickly to expand on the current offering of services by leveraging its existing telemedicine infrastructure to provide access to patients across the state of Washington. The Company will also evaluate the current services offered to determine growth in new and complimentary medical services, add new lines of revenue from insurable services, and expand overall patient care. The Company will also launch its subscription-based telemedicine offering at $199/year designed to support the needs of uninsured American with urgent and acute care needs.

Our goal remains committed to establishing a national network of healthcare clinics to help millions of American gain access to affordable and accessible quality care, said Prad Sekar, CEO, CB2 Insights. With the expansion into Washington by way of acquisition, we welcome the opportunity to leverage our multi-disciplinary model to expand quickly on the services delivered by JMC to include telemedicine, sub-specialty, allied health and other complementary services for current and new patients of the practice.

JMC represents the second acquisition by the Company since its recently announced oversubscribed private placement of CAD 5.13 million in September 2020. The acquisition is also part of a 3-pronged growth model which includes growth from the current infrastructure, new services and acquisitions. The Companys experienced management team continues to develop a robust pipeline of accretive and strategic acquisition targets that are revenue generating, profitable and offer significant opportunities for growth. The Company paid a total cash consideration of CAD 0.37 million for JMC. Terms of the transaction include a customary transition by the previous owners for a period of up to 1 year to ensure successful continuity of care for patients in the practice. JMC reported revenues in 2019 of CAD 0.7 million and net income of CAD 0.1 million.

About CB2 Insights

CB2 Insights (CSE:CBII OTCQB:CBIIF) is a healthcare services and technology company, working to positively impact patient health outcomes. The Companies mission to improve the lives of patients through the prevention and treatment of health conditions and using proprietary technology to monitor, assess, and generate insights to help improve patient outcomes. The Company owns and operates a proprietary virtual telehealth platform, and a network of over 30 medical clinics across 14 states in the US, providing multi disciplinary, primary and urgent care services to over 120,000 patients annually.

The Company has created works primarily to roster and treat patients seeking traditional and alternative treatments due to the ineffectiveness of conventional medicine, inability to find support through their existing care network, or in some cases, inability to access a primary care network. The Company offers both primary care via a traditional insurable services model and a disruptive low-cost subscription based urgent care offering for patients seeking immediate need to a healthcare provider via telehealth.

The Company differentiates itself by being one of the largest integrative medical practices in the US that owns its own proprietary technology, data analytical assets, and clinical research expertise to support new market expansion, market access, data collection and analysis and drug discovery.

The Company operates a proprietary electronic health record platform Sail (Sail) to document, treat, monitor and report on patient health outcomes. Developed in 2015, Sail is used internally across all of the Companys clinical operations. Sail features a robust telemedicine platform that the Company uses to provide care to its National patient base. To support patient care and positive health outcomes, the Company is also focused on advancing safety and efficacy research surrounding alternative health treatments by monitoring and assessing Real-World Data (RWD) and providing Real-World Evidence (RWE) through our proprietary technology, data analytics, and a full service contract research organization.

For more information please visit http://www.cb2insights.com or contact:

Investor RelationsJonathan L. Robinson CFAOak Hill Financialjrobinson@oakhillfinancial.ca416-669-1001

Forward Looking Statements

Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in CB2s filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.

Forward-looking statements may include, without limitation, statements regarding the Companys unaudited financial results and projected growth.

Although CB2 has attempted to identify important factors that could cause actual results, performance or achievements todiffer materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; investing in target companies or projects which have limited or no operating history and are subject to inconsistent legislation and regulation; change in laws; reliance on management; requirements for additional financing; competition; hindering market growth and state adoption due to inconsistent public opinion and perception of the medical-use and recreational-use marijuana industry and; regulatory or political change.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.

Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. CB2 disclaims any intention or obligation to update or revise such information, except as required by applicable law, and CB2 does not assume any liability for disclosure relating to any other company mentioned herein.

No securities regulator or exchange has reviewed, approved, disapproved, or accepts responsibility for the content of this news release.

See the article here:
CB2 Insights enters Washington with acquisition of Primary Care Medical Clinic with $0.7 million in Revenue and Positive EBITDA - BioSpace

Newswise Jeffery Dusek, PhD, Director of Research at University Hospitals (UH) Connor Integrative Health Network and Associate Professor in the Department of Family Medicine and Community Health at Case Western Reserve University, and colleagues were recently awarded a 3-year, $2+ million grant from the National Center of Complementary and Integrative Health, part of the National Institutes of Health.

Dr. Dusek and M. Diane McKee, MD, MS, Chair of the Department of Family Medicine & Community Health at UMass Medical School and UMass Memorial Medical Center, will co-lead a multi-center study whereby acupuncture will be utilized in the emergency departments at three academic medical centers across the country, including UH Cleveland Medical Center, Vanderbilt and University of California San Diego, to manage pain and ideally reduce prescription of opioid medications.

The study will leverage the BraveNet Practice Based Research Network, which is a leading group of 15 integrative medicine clinics across the nation. Dr. McKee serves as Director of the Coordinating Center for BraveNet and has collaborated extensively with Dr. Dusek.

Dr. Dusek is experienced in studying acupuncture for pain, having conducted past research on Acupuncture and the Effect of Complementary and Alternative Medicine on Pain Among Inpatients, along with other studies. Dr. McKee recently completed a Patient-Centered Outcomes Research Institute (PCORI) funded study, Acupuncture Approaches to Decrease Disparities in Outcomes of Pain Treatment, which compared individual and group acupuncture delivered in primary care for chronic musculoskeletal pain.

A total of 150 subjects (50 at each of the three sites) will be randomized to either acupuncture or usual care. In addition, emergency department patients and providers at each site will participate in structured interviews to support implementation of a large-scale, multi-site, randomized trial in the future.

According to published studies, pain accounts for up to 78 percent of emergency department patient visits in the United States, said Dr. Dusek. University Hospitals made a commitment to evaluate alternative treatments for pain in order to help mitigate the opioid epidemic impacting our communities. Positive results from this study and a future large-scale trial could provide critical evidence to support inclusion of acupuncture in emergency departments across the country. If successful, such an expansion could provide Americans with additional non-pharmacologic methods for robust pain management and ideally reduce patients opioid use.

###

About University Hospitals

Founded in 1866, University Hospitals serves the needs of patients through an integrated network of 18 hospitals, more than 50 health centers and outpatient facilities, and 200 physician offices in 16 counties throughout northern Ohio.The systems flagship academic medical center, University Hospitals Cleveland Medical Center, located in Clevelands University Circle, is affiliated with Case Western Reserve University School of Medicine. The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top childrens hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; University Hospitals Harrington Heart & Vascular Institute, a high-volume national referral center for complex cardiovascular procedures; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. UH is home to some of the most prestigious clinical and research programs in the nation, including cancer, pediatrics, women's health, orthopedics, radiology, neuroscience, cardiology and cardiovascular surgery, digestive health, transplantation and urology. UH Cleveland Medical Center is perennially among the highest performers in national ranking surveys, including Americas Best Hospitals from U.S. News & World Report. UH is also home to Harrington Discovery Institute at University Hospitals part of The Harrington Project for Discovery & Development. UH isone of the largest employers in Northeast Ohio with 28,000 physicians and employees.Advancing the Science of Health and the Art of Compassion is UHs vision for benefitting its patients into the future, and the organizations unwavering mission is To Heal. To Teach. To Discover.Follow UH on LinkedIn, Facebook @UniversityHospitalsand Twitter @UHhospitals. For more information, visitUHhospitals.org.

About Case Western Reserve University

Case Western Reserve University is one of the country's leading private research institutions. Located in Cleveland, we offer a unique combination of forward-thinking educational opportunities in an inspiring cultural setting. Our leading-edge faculty engage in teaching and research in a collaborative, hands-on environment. Our nationally recognized programs include arts and sciences, dental medicine, engineering, law, management, medicine, nursing and social work. About 5,100 undergraduate and 6,700 graduate students comprise our student body. Visitcase.eduto see how Case Western Reserve thinks beyond the possible.

Visit link:
University Hospitals Connor Integrative Health Network to Study Acupuncture in the ED with $2+ Million Grant - Newswise

Researchers have long known that many people (mostly women) suffering from anorexia face a high risk of death. But, until now, they didnt know what causes the eating disorder to turn fatal.

In a research letter published in the Oct. 26 edition of Nature Metabolism, Yale researchers describe a specific neuron that appears to play an important role in whether anorexia becomes deadly.

They also discovered a potential treatment: a high-fat diet.

Over the last 25 years, our work has focused on understanding what drives hunger, said author Tamas Horvath, the Jean and David W. Wallace Professor of Comparative Medicine and professor of neuroscience and of obstetrics, gynecology, and reproductive sciences. We wondered if neurons in the brain which are working at a high level when someone is dieting could be participating in some aspect of the disease.

For the study, the researchers looked at a specific neuron that is active during food restriction, called the hypothalamic agouti-related peptide (AgRP), in food-restricted, exercising mice. They found a direct relationship between the workings of the neuron and the animals likelihood of dying. In fact, all animals on a food-restricted, high-exercise diet whose AgRP neurons were inhibited died within 72 hours.

If we diminished these neurons in animals who ate little and exercised compulsively, they died, said Horvath, who is also chair of the Department of Comparative Medicine and director of the Yale Program in Integrative Cell Signaling and Neurobiology of Metabolism.

Lowering levels of these neurons proved fatal, Horvath said, because they are needed to help the body access alternative forms of fuel namely fat in the absence of eating, combined with intense exercise. If these neurons dont function, you are not able to mobilize fuels from fat stores, he said.

But when they provided fatty food to the mice with decreased AgRP activity they found that death [was] completely prevented. This finding could suggest a new tactic for treating anorexia in people, Horvath said. If you are a person dying from anorexia and eat foods containing elevated fat, you may survive, he said.

Anorexia nervosa is an eating disorder that affects mainly adolescent girls. Those with the disorder severely restrict their eating, fear gaining weight, and exercise compulsively. Some 20 million women suffer from anorexia, which has the highest mortality rate of any mental illness.

Horvath and other Yale researchers are now extending their research to identify which fats may work best in preventing anorexia from becoming lethal. Many people with this disorder are in the care of medical professionals, and theres an opportunity to bring these findings to the human population, he said.

Other Yale researchers who contributed to the research letter include first author Maria Miletta, postdoctoral associate in comparative medicine; Onur Iyilikci, postdoctoral associate in comparative medicine; Marya Shanabrough, research associate in comparative medicine; Matija Sestan-Pesa, postdoctoral associate in comparative medicine; Caroline Zeiss, professor of comparative medicine; and Marcelo Dietrich, associate professor of comparative medicine and of neuroscience. The work was supported by the Klarman Family Foundation and the National Institutes of Health.

See the original post:
Yale finds neuron behind fatal anorexia, and solution in high-fat diet - Yale News

Global Nutrigenomics Market Research Report offers a in-depth view on market trends, forecast statistics, company profile, growth drivers and latest industry insights. The report covers all the Nutrigenomics type, applications, deployment models, research regions. A deep-dive analysis on leading Nutrigenomics industry players, their market share, production volume, gross margin analysis from 2015-2019 is provided. Challenges to the Nutrigenomics development, growth opportunities, market drivers, restraints are described in this report.

The market value, market share, production and gross margin of Nutrigenomics is covered for every type, application, and geographical regions. Also, import-export scenario, regional SWOT analysis, and market status is elaborated. Nutrigenomics Forecast covers type, application and regional forecast for market value, volume, and consumption from 2020 to 2026. Industry barriers, investment feasibility, and opportunities to the new Nutrigenomics market players are analyzed in this report.

Global Nutrigenomics market is subdivided based on type, application and research regions. Top regions studied in this report include North America, Europe, Asia-Pacific, South America, Middle East & Africa. For each region, production value and growth rate is covered from 2015 to 2019. The information on market concentration and market maturity analysis will lead to investment feasibility.

Get Free Sample(COVID-19 Impact Analysis Updated Sample):@:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nutrigenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/145967#request_sample

Major players covered in this report:

DSM N.V.Genomix Nutrition, Inc.DanoneNutrigenomics New ZealandMetagenics, IncDNALIFECura Integrative MedicineNutraGeneBASF SEGX SciencesNutrigenomixWellGen Inc.XCODE Life Sciences Pvt. Ltd.

Global Nutrigenomics Market Segmentation:

By Type:

Reagents & KitsPharmaceuticalFood and NutritionServices

By Application:

Comprises ObesityDiabetesAnti-AgingChronic DiseasesOthers

Market drivers explain the emerging countries and Nutrigenomics growth. Also, the limitations, opportunities, latest industry plans, and policies are offered. Industry chain analysis explains upstream raw material suppliers, key market players, production process analysis, Nutrigenomics manufacturing cost structures, and global market share of Nutrigenomics in 2019. This in-depth study explains the cost of raw materials, labor cost, marketing channels and major downstream buyers of Nutrigenomics.

Get Up to 30% Off on purchasing this report, Ask Here for Discount @:

https://www.globalmarketers.biz/discount_inquiry/discount/145967

This study analyzes the Nutrigenomics industry market status and forecast statistics explaining the production, revenue, consumption ratio, and historic market trends. All the manufacturers, market share, company profiles, production capacity, and gross margin analysis of Nutrigenomics is presented in this report. The industry breakdown based on product type, applications, regions, and manufacturer will provide sophisticated Nutrigenomics market view. Recent Nutrigenomics developments, opportunities, challenges, and business strategies are explained. The influencing factors, product launches, mergers and acquisition of Nutrigenomics is covered in this study.

The report also explains the demand and supply side of Nutrigenomics, revenue estimates, competitive scenario, and sales data. Nutrigenomics value chain, market status, and price trends are explained in detail. Nutrigenomics industry presence across different geographies covers the regions like North America, Europe, Asia-Pacific, Middle East & Africa, and South America. Further, the countries like United States, Canada, Mexico, China, Japan, Korea, India, Australia, Indonesia, Singapore, Germany, United Kingdom, France, Italy, Spain, Russia, Brazil, Argentina, UAE, Saudi Arabia, Turkey and the rest are analyzed in this report.

Enquire For Complete Sample Report Copy Or Request For Customization:

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nutrigenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/145967#inquiry_before_buying

Reasons To Buy This Report:

Nutrigenomics Report Effectively Addresses The Below Queries.

Explore Detailed Table Of Content With Table Of Figures: @

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-nutrigenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/145967#table_of_contents

Excerpt from:
Global Nutrigenomics Market Demand is Increasing Rapidly in Recent Years With Advanced Technology to Improve Product Facilities Factors to 2027 | DSM...